MA32388B1 - Immunomodulation par des inhibiteurs d'iap - Google Patents

Immunomodulation par des inhibiteurs d'iap

Info

Publication number
MA32388B1
MA32388B1 MA33406A MA33406A MA32388B1 MA 32388 B1 MA32388 B1 MA 32388B1 MA 33406 A MA33406 A MA 33406A MA 33406 A MA33406 A MA 33406A MA 32388 B1 MA32388 B1 MA 32388B1
Authority
MA
Morocco
Prior art keywords
methods
inhibitors
prevention
immunomodulation
ipa
Prior art date
Application number
MA33406A
Other languages
Arabic (ar)
English (en)
Inventor
Brant G Firestone
Glenn Dranoff
Leigh Zawel
Christopher S Straub
Michael Dougan
Original Assignee
Novartis Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32388(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Dana Farber Cancer Inst Inc filed Critical Novartis Ag
Publication of MA32388B1 publication Critical patent/MA32388B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des adjuvants immunitaires contenant des inhibiteurs d'iap, comprenant des mimétiques de smac. L'invention concerne en outre des compositions pharmaceutiques et des vaccins contenant un inhibiteur d'iap et un antigène. La présente invention concerne en outre des procédés d'amélioration d'une réponse immunitaire par administration d'un inhibiteur d'iap, des procédés de traitement ou de prévention du cancer, des procédés de traitement ou de prévention des infections, des procédés de traitement de troubles auto-immuns, et des procédés de potentialisation de la production de cytokine ou d'anticorps.
MA33406A 2008-05-16 2010-12-08 Immunomodulation par des inhibiteurs d'iap MA32388B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5394708P 2008-05-16 2008-05-16
PCT/US2009/043874 WO2009140447A1 (fr) 2008-05-16 2009-05-14 Immunomodulation par des inhibiteurs d’iap

Publications (1)

Publication Number Publication Date
MA32388B1 true MA32388B1 (fr) 2011-06-01

Family

ID=40823320

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33406A MA32388B1 (fr) 2008-05-16 2010-12-08 Immunomodulation par des inhibiteurs d'iap

Country Status (17)

Country Link
US (4) US9750729B2 (fr)
EP (3) EP2698158B1 (fr)
JP (3) JP5779091B2 (fr)
KR (1) KR20110022608A (fr)
CN (1) CN102099035A (fr)
AU (1) AU2009246347A1 (fr)
BR (1) BRPI0912692A2 (fr)
CA (1) CA2724720A1 (fr)
CL (1) CL2009001195A1 (fr)
EA (1) EA201071316A1 (fr)
ES (2) ES2882855T3 (fr)
IL (1) IL209203A0 (fr)
MA (1) MA32388B1 (fr)
MX (1) MX2010012231A (fr)
TW (1) TW201006834A (fr)
WO (1) WO2009140447A1 (fr)
ZA (1) ZA201008176B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (fr) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Composés de liaison au domaine iap bir
CN102099035A (zh) * 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节
JP4995211B2 (ja) * 2008-09-29 2012-08-08 キヤノン株式会社 電子写真画像形成装置
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
KR20160030099A (ko) * 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
AU2017253560B2 (en) * 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
WO2020027225A1 (fr) * 2018-07-31 2020-02-06 ファイメクス株式会社 Composé hétérocyclique
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
PH12022550721A1 (en) 2019-09-25 2024-05-13 Debiopharm Int Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
ES2415336T3 (es) * 2003-04-11 2013-07-25 Survac Aps Vacuna terapéutica contra el cáncer
CN1938332B (zh) * 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
WO2005084317A2 (fr) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Petites molecules dimeres inductrices d'apoptose
AU2005228950B2 (en) * 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
US20080234042A1 (en) 2004-05-02 2008-09-25 Hiroshi Uemura Game System
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (fr) 2006-10-12 2008-04-17 Novartis Ag Composes organiques
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
AU2007325280B2 (en) * 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
EP2126188A1 (fr) 2006-12-26 2009-12-02 Arçelik Anonim Sirketi Lave-linge/sèche-linge avec grandeur de sortie provenant du capteur d'humidité entrée sélectivement vers l'unité de commande
WO2008109057A1 (fr) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Composés organiques et leurs utilisations
CN102099035A (zh) * 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节

Also Published As

Publication number Publication date
CN102099035A (zh) 2011-06-15
US20110135691A1 (en) 2011-06-09
CL2009001195A1 (es) 2010-06-11
US9750729B2 (en) 2017-09-05
EP2698158A1 (fr) 2014-02-19
US20200345714A1 (en) 2020-11-05
EP2296650B1 (fr) 2020-05-06
ES2791957T3 (es) 2020-11-06
TW201006834A (en) 2010-02-16
WO2009140447A1 (fr) 2009-11-19
ES2882855T3 (es) 2021-12-02
BRPI0912692A2 (pt) 2017-03-21
AU2009246347A1 (en) 2009-11-19
MX2010012231A (es) 2011-02-18
IL209203A0 (en) 2011-01-31
JP2011524339A (ja) 2011-09-01
EP2296650A1 (fr) 2011-03-23
EP2698158B1 (fr) 2021-06-30
CA2724720A1 (fr) 2009-11-19
US20220296581A1 (en) 2022-09-22
JP2015129170A (ja) 2015-07-16
ZA201008176B (en) 2011-08-31
JP2016094429A (ja) 2016-05-26
JP5986655B2 (ja) 2016-09-06
US10786491B2 (en) 2020-09-29
EA201071316A1 (ru) 2011-06-30
US11382905B2 (en) 2022-07-12
KR20110022608A (ko) 2011-03-07
EP3701947A1 (fr) 2020-09-02
JP5779091B2 (ja) 2015-09-16
US20170368047A1 (en) 2017-12-28
JP6030739B2 (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
MA32388B1 (fr) Immunomodulation par des inhibiteurs d'iap
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
MX2012010793A (es) Composiciones y metodos para la eliminacion de biopeliculas.
WO2012045001A3 (fr) Anticorps dirigés contre le virus de la grippe, immunogènes et leurs utilisations
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX374291B (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
ATE426412T1 (de) Adjuvante influenza-vakzine
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
CY1115235T1 (el) Συνθεσεις και μεθοδοι ενισχυσης του ανοσοποιητικου συστηματος
UA104585C2 (ru) Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
WO2008033966A3 (fr) Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
MX2012001495A (es) Polipeptidos de porphyromonas gingivalis.
WO2014205199A3 (fr) Compositions et méthodes de potentialisation de la réponse immunitaire, de stimulation de l'immunothérapie et d'augmentation de la puissance d'un vaccin
WO2007150008A3 (fr) Polypeptides issus du virus de la peste porcine africaine utilisés en tant que vaccins à usage préventif et thérapeutique
WO2015031778A3 (fr) Compositions et méthodes pour le traitement ou la prévention de la tuberculose
WO2016020702A8 (fr) Anticorps anti-ténascine-c et utilisations
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими
WO2015144732A3 (fr) Utilisations de facteurs inhibiteurs de la migration de macrophages de parasite
PH12018501646A1 (en) Compositions and methods for treating infections
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.